Syn-2869. Antifungal

Drugs of the Future

Volumn 24, Issue 1, 1999, Pages 30-37

  Fromtling, Robert A ^a,b   Castaner J ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 1 PIPERAZINYL]PHENYL] 2 [4 (TRIFLUOROMETHOXY)BENZYL] 2,4 DIHYDRO 3H 1,2,4 TRIAZOL 3 ONE; 4 [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 1 PIPERAZINYL]PHENYL] 2,4 DIHYDRO 2 [4 (TRIFLUOROMETHOXY)BENZYL] 1,2,4 TRIAZOL 3 ONE; 4 [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 1 PIPERAZINYL]PHENYL] 2,4 DIHYDRO 2 [[4 (TRIFLUOROMETHYL)PHENYL]METHYL] 3H 1,2,4 TRIAZOL 3 ONE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; SYN 2903; SYN 2921; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG STRUCTURE; DRUG SYNTHESIS; LUNG MYCOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION;

EID: 0344507371     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.01.483809     Document Type: Article

References (38)

1. Daneshtalab, M., Bathini, Y., Nguyen, D. et al. (Synphar Laboratories, Inc.; Taiho Pharmaceutical Co., Ltd.). New triazoles as therapeutic agents for fungal infections. EP 889881, WO 9831675.
2. Abel, M.D., Bathini, Y., Ha, C. et al. Syn-2869, novel broad-spectrum antifungal triazole: Synthesis and structure activity relationships. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F148.
3. Jarvis, W.R. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995, 20: 1526-30.
4. Pfaller, M.A. Epidemiology and control of fungal infections. Clin Infect Dis 1994, 19(Suppl. 1): S8-13.
5. Pfaller, M.A. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996, 22(Suppl. 2): S89-94.
6. Beck-Sague, C.M., Jarvis, W.R. and the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993, 167: 1247-51.
7. Polis, M.A., Kovacs, J.A. Fungal infections in patients with acquired immunodeficiency syndrome. In: AIDS. Epidemiology, Diagnosis, Treatment and Prevention, 4th Edition, V.T. DeVita, S. Hellman and S.A. Rosenberg (Eds.), Lippincott-Raven, Philadelphia, 1997.
8. Dupont, B., Denning, D.W., Marriott, D., Sugar, A., Viviani, M.A., Sirisanthana, T. Mycoses in AIDS patients. J Med Vet Mycol 1994, 32(Suppl. 1): 65-77.
9. Groll, A.H., Shah, P.M., Mentzel, C., Schneider, M., Just-Nuebling, G., Huebner, K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996, 33: 23-32.
10. McNeil, M.M. Candida. In: Hospital Epidemiology and Infection Control, C.G. Mayhall (Ed.), Williams and Wilkins, Baltimore 1996, 408-19.
11. Hamilton, A.J., Goodley, J. Virulence factors of Cryptococcus neoformans. Curr Top Med Mycol 1996, 7: 19-42.
12. Dupont, B., Graybill, J.R., Armstrong, D., Larouche, R., Tuoze, J.E., Wheat, L.J. Fungal infections in AIDS patients. J Med Vet Mycol 1992, 30(Suppl. 1): 19-28.
13. Armstrong, D. Treatment of opportunistic fungal infections. Clin Infect Dis 1993, 16: 1-9.
14. Fan-Havard, P., Capana, D., Smith, S.M., Mangia, A., Eng, R.H.K. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 1991, 35: 2302-5.
15. Wingard, J.R., Merz, W.G., Rinaldi, M.G., Johnson, T.R., Karp, J.E., Saral, R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991, 325: 1274-7.
16. Heinic, G.S., Stevens, D.A., Greenspan, D., MacPhail, L.A., Dodd, C.L., Stringari, S., Strull, W.M., Hollander, H. Fluconazole-resistant Candida in AIDS patients. Oral Surg Oral Med Oral Pathol 1993, 76: 711-5.
17. Revankar, S.G., Kirkpatrick, W.R., McAtee, R.K., Dib, O.P., Fothergill, A.W., Redding, S.W., Rinaldi, M.G., Hilsenbeck, S.G., Patterson, T.F. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance. Am J Med 1998, 105: 7-11.
18. Baily, G.G., Perry, F.M., Denning, D.W., Mandal, B.K. Fluconazole resistant candidosis in an HIV cohort. AIDS 1993, 8: 787-92.
19. Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E., Trautmann, M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994, 32: 2092-8.
20. Rex, J.H., Rinaldi, M.G., Pfaller, M.A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995, 39: 1-8.
21. Marr, K.A., White, T.C., vanBurik, J.A.H., Bowden, R.A. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997, 25: 908-10.
22. Nolte, F.S., Parkinson, T., Falconer, D.J., Dix, S., Williams, J., Gilmore, C., Geller, R., Wingard, J.R. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997, 41: 196-9.
23. Denning, D.W. Treatment of invasive aspergillosis. J Infect 1994, 28(Suppl. 1): 25-33.
24. Denning, D.W., Follansbee, S.E., Scolaro, M., Norris, S., Edelstein, H., Stevens, D.A. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. New Engl J Med 1991, 324: 654-62.
25. De Repentigny, L., Reiss, E. Current trends in immunodiagnosis of candidiasis and aspergillosis. Rev Infect Dis 1984, 6: 301-12.
26. Kurup, V.P., Kumar, A. Immunodiagnosis of aspergillosis. Clin Microbiol Rev 1991, 4: 439-56.
27. Rinaldi, M.G. Invasive aspergillosis. Rev Infect Dis 1983, 5: 1061-77.
28. Fromtling, R.A. Fluconazole (UK-49,858). Drugs Fut 1985, 10: 983-4.
29. Fromtling, R.A. Fluconazole (Diflucan®): A new antifungal triazole. Drugs Today 1990, 26: 547-56.
30. Goa, K.L., Barradell, L.B. Fluconazole: An update. Drugs 1995, 50: 658-90.
31. Groll, A.M., Piscitelli, S.C., Walsh, T.J. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998, 44: 343-501.
32. Fothergill, A.W., Salama, S.M., Rinaldi, M.G. An in vitro head-to-head comparison of Syn2836, Syn2869, Syn2903, Syn2921, amphotericin B, fluconazole, and itraconazole against a spectrum of 90 clinically-significant fungi. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst J117.
33. Gibb, A.P., van den Elzen, H. Activity of Syn2869, fluconazole, and itraconazole against 139 consecutive yeast isolates from normally-sterile sites. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F147.
34. Salama, S.M., Gandhi, A., Atwal, H., Simon, J., Khan, J., Micetich, R.G., Daneshtalab, M. Syn2869, a new potent antifungal triazole for the treatment of systemic and superficial fungal infections: In vitro activity against clinical isolates of yeast and dermatophytes. 38th Intersci Cont Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F150.
35. Johnson, E.M., Sezekly, A., Warnock, D.W. In vitro antifungal activity of Syn2869 against emerging and less common mold pathogens. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F153.
36. Salama, S.M., Atwal, H., Gandhi, A., Khan, J., Montaseri, H., Poglod, M., Micetich, R.G., Daneshtalab, M. Syn2869, a new potent antifungal triazole: In vivo efficacy against systemic infections of Torulopsis glabrata, and Cryptococcus neoformans in immunosuppressed mice. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F151.
37. Furukawa, T., Saito, H., Uji, T., Nishida, K., Higashitani, F., Unemi, N., Yamaguchi, H. In vivo activity of Syn2869, a novel antifungal triazole in murine models of deep mycosis. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F149.
38. Khan, J.K., Montaseri, H., Poglod, M., Bu, H.Z., Salama, S., Micetich, R.G., Daneshtalab, M. Pharmacokinetics and oral bioavailability of novel triazole derivative Syn2869 - A potent new antifungal agent and its comparison with itraconazole. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst F152.